

Si-Yang Liu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4233043/publications.pdf>

Version: 2024-02-01

25
papers

1,088
citations

759233

12
h-index

642732

23
g-index

26
all docs

26
docs citations

26
times ranked

1222
citing authors

#	ARTICLE	IF	CITATIONS
1	Prediction of unfavourable response to checkpoint blockade in lung cancer patients through an integrated tumour-immune expression score. <i>Translational Oncology</i> , 2022, 15, 101254.	3.7	4
2	What We Have Learned From Adjuvant Therapy for Resected EGFR-Mutant Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 217-220.	1.6	6
3	Real-World Survival Outcomes Based on EGFR Mutation Status in Chinese Patients With Lung Adenocarcinoma After Complete Resection: Results From the ICAN Study. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100257.	1.1	11
4	Clinical Characteristics and Outcomes in Advanced KRAS-Mutated NSCLC: A Multicenter Collaboration in Asia (ATORG-005). <i>JTO Clinical and Research Reports</i> , 2022, 3, 100261.	1.1	9
5	Predictive value of TCR V β 2-J β 2 profile for adjuvant gefitinib in EGFR mutant NSCLC from ADJUVANT-CTONG 1104 trial. <i>JCI Insight</i> , 2022, 7, .	5.0	17
6	Poor prognosis of intra-tumoural TRBV6 variants in EGFR-mutant NSCLC: Results from the ADJUVANT-CTONG1104 trial. <i>Clinical and Translational Medicine</i> , 2022, 12, e775.	4.0	8
7	Predictive value of intra-tumoural TCR β rearrangements in precisely selecting adjuvant therapy for EGFR-mutant non-small-cell lung cancer. <i>Clinical and Translational Discovery</i> , 2022, 2, .	0.5	1
8	Biomarker-Driven Studies With Multi-targets and Multi-drugs by Next-Generation Sequencing for Patients With Non-Small-Cell Lung Cancer: An Open-Label, Multi-center, Phase II Adaptive Umbrella Trial and a Real-World Observational Study (CTONG1702&CTONG1705). <i>Clinical Lung Cancer</i> , 2022, 23, e395-e399.	2.6	4
9	Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non-Small Cell Lung Cancer. <i>Cancer Discovery</i> , 2022, 12, 1690-1701.	9.4	84
10	Perioperative targeted therapy for oncogene-driven NSCLC. <i>Lung Cancer</i> , 2022, 172, 160-169.	2.0	15
11	Sintilimab versus pembrolizumab in monotherapy or combination with chemotherapy as first-line therapy for advanced non-small cell lung cancer: Results from phase 2, randomized clinical trial (CTONG1901).. <i>Journal of Clinical Oncology</i> , 2022, 40, 9032-9032.	1.6	9
12	Efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer harboring ERBB2 exon 20 insertions and non-ERBB2 exon 20 insertions.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2591-2591.	1.6	0
13	Toward a cure for lung cancer: important advances in operable non-small cell lung cancer. <i>Science Bulletin</i> , 2022, 67, 1402-1405.	9.0	8
14	Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-III A (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 713-722.	1.6	159
15	Using deep learning to predict anti-PD-1 response in melanoma and lung cancer patients from histopathology images. <i>Translational Oncology</i> , 2021, 14, 100921.	3.7	34
16	Unmet Clinical Demand for Patients With Unresectable Stage III NSCLC Having Actionable Genetic Alterations. <i>Journal of Thoracic Oncology</i> , 2021, 16, 712-714.	1.1	1
17	Genomic signatures define three subtypes of EGFR-mutant stage III non-small-cell lung cancer with distinct adjuvant therapy outcomes. <i>Nature Communications</i> , 2021, 12, 6450.	12.8	48
18	Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC). <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 1355-1364.	4.1	39

#	ARTICLE	IF	CITATIONS
19	Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma. EBioMedicine, 2020, 60, 102990.	6.1	95
20	Concomitant genetic alterations having greater impact on the clinical benefit of EGFR-TKIs in EGFR mutant advanced NSCLC than BIM deletion polymorphism. Clinical and Translational Medicine, 2020, 10, 337-345.	4.0	7
21	Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non-small cell lung cancer patients. Biomarker Research, 2020, 8, 22.	6.8	37
22	Safety of EGFR-TKIs for EGFR mutation-positive non-small cell lung cancer. Expert Opinion on Drug Safety, 2020, 19, 589-599.	2.4	13
23	Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With EGFR Mutation. Journal of Thoracic Oncology, 2018, 13, 1668-1675.	1.1	111
24	Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer. Lung Cancer, 2018, 125, 86-92.	2.0	63
25	EGFR mutation correlates with uninfamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer. OncoImmunology, 2017, 6, e1356145.	4.6	305